Understanding PhV today – a basic training course on the principles and practice of global PhV for those working in drug safety.
This comprehensive three-day course has been designed to provide an introductory guide for all those concerned with pharmacovigilance. The interactive programme will cover topics from basic pharmacovigilance principles and terminologies through to the current regulatory framework and its global impact, including drug surveillance in the EU, US and Japan. Proactive pharmacovigilance pre- and post-marketing will be addressed as will risk management, the challenges of causality assessments and effective signal detection.
Our panel of experts will offer practical guidance throughout the course and use real-world examples and case studies to contribute to the development of your knowledge. There will also be ample opportunity to share experiences with the speakers and fellow professionals, which will further enhance your understanding of pharmacovigilance issues.
Key topics to be addressed include:
Anybody involved and interested in the daily practice of pharmacovigilance, including pharmaceutical physicians and those working in:
A real-world example of the development of a successful EU RMP
A practical case study with valuable hands-on experience
Glyn Belcher (More...) (21-23 Jun 2021, 6-8 Dec 2021)
Dr Glyn Belcher has over 25 years experience in clinical development and drug safety in the pharmaceutical industry. He qualified in medicine from Oxford and Cambridge and received his PhD in neuropharmacology from the latter university. After a number of years in hospital medicine he joined Schering and worked in clinical research in the UK affiliate before moving to headquarters in Berlin, first as head of cardiovascular clinical research and later as head of a new safety department covering clinical development activities. He then became Director of Clinical Drug Safety and EU QPPV for Takeda Europe and a global safety officer of Takeda headquarters in Osaka. His most recent position in the industry was Vice President of Drug Safety and Risk Management for all ex-USA territories of Biogen Idec and EU QPPV for the company. He now has his own consultancy company, PV Consultancy Ltd, and works with a number of companies in the areas of clinical development and drug safety, as well as undertaking an increasing commitment to teaching and training in these areas.
21-23 Jun 2021 Face-to-face, (venue not yet confirmed) |
|||
21-23 Jun 2021 Face-to-face (venue not yet confirmed) |
GBP 1,849 1,549 EUR 2,589 2,169 USD 2,884 2,416 Until 10 May* |
Enrol now
to attend Face-to-face (venue not yet confirmed) |
|
6-8 Dec 2021 Face-to-face, (venue not yet confirmed) |
|||
6-8 Dec 2021 Face-to-face (venue not yet confirmed) |
GBP 1,849 1,549 EUR 2,589 2,169 USD 2,884 2,416 Until 25 Oct* |
Enrol now
to attend Face-to-face (venue not yet confirmed) |
|
Learn more about our face-to-face and webinar training formats.
* Note the early booking discount cannot be combined with any other offers or promotional code